Clinical Trial Update: PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI [Phase 3]

View source ↗

Summary

An update on a Phase 3 trial evaluating PSMA PET imaging as an additive diagnostic tool for prostate cancer in men with negative or equivocal MRI results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Prostate Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING